表紙
市場調查報告書

新冠狀病毒COVID-19檢驗:症狀,無症狀,免疫血清學

Coronavirus Covid-19 Testing: Symptoms, Asymptomatic and Serology for Immunity

出版商 WinterGreen Research, Inc. 商品編碼 931145
出版日期 內容資訊 英文 103 Pages; 20 Tables, Charts & Figures
訂單完成後即時交付
價格
新冠狀病毒COVID-19檢驗:症狀,無症狀,免疫血清學 Coronavirus Covid-19 Testing: Symptoms, Asymptomatic and Serology for Immunity
出版日期: 2020年04月05日內容資訊: 英文 103 Pages; 20 Tables, Charts & Figures
簡介

冠狀病毒的流行預計將持續到至少2021年1月。PCR測試非常耗時,需要執行多個步驟才能執行單個測試,這會導致錯誤並出現假陽性的問題。當美國報導第一例COVID-19時,只有兩個實驗室核准進行COVID-19的檢測。目前正在努力通過將檢查能力提供給州等公共衛生實驗室來擴展檢查能力。

本報告提供全球新冠狀病毒COVID-19檢驗市場相關調查,彙整美國的檢驗情況和國際反應,各地區檢驗趨勢,參與企業的簡介等相關資訊。

摘要整理

第1章 美國COVID-19檢驗 - CDC和供應商的檢驗提供能力

  • 市場推動力
  • COVID-19檢驗
  • COVID-19檢驗設備
  • COVID-19檢驗費用

第2章 美國COVID-19測試延誤和國際回應

  • 大量延遲檢驗
  • 政府與開放市場管理
  • 從血液樣本中提取病毒

第3章 COVID-19檢驗的各地區分析

  • 全球COVID-19感染者數
  • 美國
  • 中國
  • 印度
  • 歐洲
  • 亞洲
  • 其他各國

第4章 COVID-19分子診斷檢驗技術

  • 冠狀病毒檢測技術的聚合酶鏈反應(PCR)
  • Panther Fusion可自動執行COVID-19分子診斷測試中涉及的複雜步驟
  • 科學家需要真正的病毒來確認診斷測試

第5章 企業簡介

第6章 COVID-19PCR檢驗:概要與趨勢

  • 快速發展的COVID-19
  • COVID-19呼吸系統疾病
  • PCR和分子診斷測試趨勢
  • 去哪裡檢查
  • 檢驗:假陰性及假陽性
  • COVID-19血清測試

WINTERGREEN RESEARCH

目錄
Product Code: SH28421314

This new study ‘US Coronavirus Covid-19 Patient Testing 2020: The Way Forward ’ describes United States testing for the rapidly evolving COVID-19 pandemic. Testing capability forecasts for PCR assay and Molecular Diagnostics are presented in two week increments for the next 6 months. Availability of Serological testing is also forecast for detection of the virus after recovery. All major vendors are included and can be compared with quantities, qualities, and test time.

‘Covid-19 Testing 2020: The Way Forward’ describes the timelines the virus is likely to take regarding quarantines and successive waves of infection. Successive waves of infection are expected to strike the US population after the shelter in place restrictions start to be lifted. Intensive testing is needed at every stage of covid-19 disease management. The testing scenarios and the vendors with good test kits are described in detail.

Successive waves of infection are expected to continue to at least January 2021. One thing that will stop them is if effective vaccine is found. The 2020 study has 96 pages, 12 tables and figures. The tables describe in enormous detail what testing kits are available and the significance of further testing. It describes testing capacity and length of time to administer testing. It describes the impact of testing and the need for serological testing as the quarantines begin to end.

PCR testing - as used by the CDC and WHO initially - is very labor intensive, and has several points along the path of doing a single test where errors may occur - which may lead to headline issues of a false positive, the test showing evidence of the virus when it's not actually there, or a false negative, suggesting someone doesn't have the virus when in fact they do.

The virus and the resulting disease, Covid-19, have hit Germany with force: According to Johns Hopkins University, the country had more than 91,000 laboratory-confirmed infections by Saturday morning, more than any other country except the United States, Italy and Spain. But with 1,275 deaths, Germany's fatality rate stood at 1.3 percent, compared with 12 percent in Italy, around 10 percent in Spain, France and Britain, 4 percent in China and 2.5 percent in the United States. Even South Korea, a model of flattening the curve, has a higher fatality rate, 1.7 percent.

When the first cases of COVID-19 were reported in the US, two labs at the CDC were the only ones permitted to conduct COVID-19 testing, using a test developed by the agency's own researchers. When the CDC tried to expand testing by providing its test kits to state and local public health labs, there were problems with the initial version of the kits, The CDC, despite initially faulty reagents making its first test kits unreliable, is now offering accurate RT-PCR Diagnostic Panels and positive and human specimen controls.

“Had {the US} done more testing from the very beginning and caught cases earlier,” said Dr. Nuzzo, of Johns Hopkins, “we would be in a far different place.”

Table of Contents

  • Abstract: Covid-19 Testing Patients with Symptoms, Patients with No Symptoms and Serology Testing for Immunity and Quarantine Avoidance

TABLE OF CONTENTS

COVID-19 TESTING IN THE US: EXECUTIVE SUMMARY

Testing and Covid-19

PCR Testing for Covid-19

Serological Testing for Covid-19

1. US COVID-19 TESTING - CDC AND VENDOR ABILITY TO PROVIDE TESTS

  • 1.1. Covid-19 PCR Testing Market Driving Forces
  • 1.2. Covid-19 Testing
  • 1.3. Covid-19 Testing Equipment Missed the Mark
    • 1.3.1. Covid-19 Need for Quarantine
    • 1.3.2. Viral Load
    • 1.3.3. Covid-19 Testing on Patients with Symptoms
    • 1.3.4. Covid-19 Serological Contact Testing
    • 1.3.5. Covid-19 Serological Testing on Social Contacts of Patients with Symptoms 35
  • 1.4. Covid-19 Testing Prices

2. DELAYS IN US COVID-19 TESTING AND INTERNATIONAL RESPONSE

  • 2.1. Broader Testing Delayed
  • 2.2. Government and Open Market Control of Testing
  • 2.3. Extracting Virus from Blood Sample

3. COVID-19 TESTING REGIONAL ANALYSIS

  • 3.1. Covid-19 Number People Affected Worldwide
  • 3.2. US
  • 3.3. China
  • 3.4. India
  • 3.5. Europe
  • 3.6. Asia
  • 3.7. Rest of World

4. COVID-19 MOLECULAR DIAGNOSTICS TESTING TECHNOLOGY

  • 4.1. Coronavirus Assay Testing Technique Polymerase Chain Reaction (PCR)
  • 4.2. Panther Fusion Automates The Complex Steps Involved In Molecular Diagnostics Covid-19 Testing
    • 4.2.1. Molecular Diagnostics
  • 4.3. Scientists Need The Actual Virus In Order To Check A Diagnostic Test

5. COVID-19 TESTING EQUIPMENT COMPANY PROFILES

  • 5.1. Abbott Laboratories
  • 5.2. Alphabet Verify
  • 5.3. Astrotech
  • 5.4. Beckman Coulter
  • 5.5. Bill Gates
  • 5.6. bioMérieux
  • 5.7. Bodysphere
  • 5.8. Center for Disease Control and Prevention CDC
    • 5.8.1. CDC Serology Test for SARS-CoV-2
  • 5.9. Co-Diagnostics, Inc.
  • 5.10. Danaher
    • 5.10.1. Cepheid is part of Danaher (NYSE:DHR).
    • 5.10.2. Cepheid
    • 5.10.3. Danaher / Integrated DNA Technologies (IDT)
  • 5.11. US FDA
  • 5.12. GenMark Diagnostics
  • 5.13. Hologic
  • 5.14. Hong Kong University of Science and Technology (HKUST)
  • 5.15. LabCorp
    • 5.15.1. LabCorp Testing
  • 5.16. Logix Smart
  • 5.17. Mammoth Biosciences
  • 5.18. Opko / BioReference Laboratories
    • 5.18.1. OPKO Health
  • 5.19. Quidel
  • 5.20. Quest Diagnostics
    • 5.20.1. Quest / Roche Partnership
    • 5.20.2. Roche IVD test / Quest Diagnostics LDT
  • 5.21. Roche Diagnostics
    • 5.21.1. Roche IVD Test for COVID-19 Offered by Quest Diagnostics
  • 5.22. Sherlock Biosciences
  • 5.23. SunSure Biotech
  • 5.24. Tianjin University China
  • 5.25. Thermo Fisher Scientific
    • 5.25.1. Thermo Fisher Scientific / Applied Biosystems
    • 5.25.2. Thermo Fisher / Dutch Diagnostics Firm Qiagen
  • 5.26. Tianjin University of China.
  • 5.27. Where to Look for More Covid-19 Information

6. COVID-19 PCR TESTING: DESCRIPTION AND DYNAMICS

  • 6.1. Rapidly Evolving COVID-19
  • 6.2. COVID-19 a Respiratory Illness
    • 6.2.1. Covid-19 Symptoms
    • 6.2.2. Diagnostic Testing for COVID-19
    • 6.2.3. Guidance for Testing
    • 6.2.4. Covid-19 Quarantine
  • 6.3. PCR and Molecular Diagnostic Testing Status
  • 6.4. Where to get Tested
  • 6.5. Testing: False Negative and False Positive
  • 6.6. Serology Testing for COVID-19

WINTERGREEN RESEARCH,

  • WinterGreen Research Methodology
  • WinterGreen Research Process
  • Market Research Study
  • WinterGreen Research Global Market Intelligence Company
  • Report Description: Revenue Models Matter

List of Figures

  • Abstract: Covid-19 Testing Patients with Symptoms, Patients with No Symptoms and Serology Testing for Immunity and Quarantine Avoidance
  • Figure 1. US Covid-19 Serological Testing to see if a Person Has Already Had the Corona Virus and Does Not Need to Be Put in Quarantine, April 1 2020 to September 1, 2020 Capability Forecasts by Two Week Intervals
  • Figure 2. US Serological Testing on People Who Have Been in Contact with Covid-19 Patients with Symptoms, May 1 to October 1, 2020
  • Figure 3. Covid-19 US Testing Market Driving Forces
  • Figure 4. Covid-19 Testing for Quarantine Implementation
  • Figure 5. CDC and Vendor implementation of Covid-19 Testing
  • Figure 6. Testing in the Next Phase of COVID-19 Outbreak: Suppression
  • Figure 7. Covid-19 Characteristics Impacted by Testing
  • Figure 8. Testing Characteristics Impacting Covid-19 Healthcare Management
  • Figure 9. Covid-19 Testing Initially Quarantined Population Management Timelines
  • Figure 10. Covid-19 Testing Second Wave Quarantined Population Management Timelines
  • Figure 11. Impact on Testing of Waves of Critically Ill Patients with Covid-19
  • Figure 12. US Covid-19 Testing Equipment Market Share Description, Number of Tests Day, Tests per Week Capability, Time to Administer, April 1, 2020
  • Figure 13. US Covid-19 Testing Equipment Company Description, Number of Tests per Day, Tests per Week Capability, April 1, 2020, Time to Administer, April 1, 2020
  • Figure 14. US Covid-19 Patient with Symptom Testing Capability April 1 2020 to September 1, 2020 Forecasts by Two Week Intervals, Testing Patients Who Present Symptoms at Care Facility or Hospital
  • Figure 15. US Serological Testing on People Who Have Been in Contact with Covid-19 Patients with Symptoms, May 1 to October 1, 2020
  • Figure 16. Abbott Virus Detection Machine
  • Figure 17. GenMark Diagnostics Coronavirus ePlex Testing System
  • Figure 18. Hologic's Panther Fusion® SARS-CoV-2 test
  • Figure 19. Quest Healthcare Provider Fact Sheet
  • Figure 20. Governor Cuomo - The Face of COVID-19 Resistance